Riparian buffer strips influence nitrogen losses as nitrous oxide and leached N from upslope permanent pasture

Riparian buffer strips can have a significant role in reducing nitrogen (N) transfers from agricultural land to freshwater primarily via denitrification and plant uptake processes, but an unintended trade-off can be elevated nitrous oxide (N2O) production rates. Against this context, our replicated bounded plot scale study investigated N2O emissions from un-grazed ryegrass pasture served by three types of riparian buffer strips with different vegetation, comprising: (i) grass riparian buffer with novel deep-rooting species, (ii) willow (young trees at establishment phase) riparian buffer, and (iii) deciduous woodland (also young trees at establishment phase) riparian buffer. The experimental control was ryegrass pasture with no buffer strip. N2O emissions were measured at the same time as total oxidized N in run-off, and soil and environmental characteristics in the ri parian buffer strips and upslope pasture between 2018 and 2019. During most of the sampling days, the no-buffer control treatment showed significantly (P < 0.05) greater N2O fluxes and cumulative N2O emissions compared to the remainder of the treatments. Our results also showed that the grass riparian buffer strip is a sink of N2O equivalent to − 2310.2 g N2O-N ha− 1 day− 1 (95% confidence interval:− 535.5 to 492). Event-based water quality results obtained during storms (12 November 2018 and 11 February 2019) showed that the willow riparian buffer treatment had the highest flow-weighted mean N concentrations (N-FWMC) of 0.041 ± 0.022 and 0.031 ± 0.015 mg N L− 1, when compared to the other treatments. Our 9-month experiment therefore, shows that ri parian buffer strips with novel deep-rooting grass can therefore potentially address emissions to both water and air. The results imply that over a shorter timeline similar to the current study, the grass riparian buffer strip can potentially address N emission to both air and water, particularly when serving a permanent pasture in similar settings as the current experiment.Fil: Dlamini, J.C. Crop and Climate Sciences. Departament of Soil; Sudáfrica. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido. University of Pretoria. Department of Plant and Soil Sciences; SudáfricaFil: Cardenas, L.M. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Tesfamarian, E.H. University of Pretoria. Department of Plant and Soil Sciences; SudáfricaFil: Dunn, R.M. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Loick, N. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Charteris, A.F. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Cocciaglia, L. Università degli Studi di Perugia. Dipartimento di Scienze Agrarie, Alimentari e Ambientali; ItaliaFil: Vangeli, Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Clima y Agua; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Agronomía. Departamento de Ingeniería Agrícola y Uso de la Tierra. Cátedra de Manejo y Conservación de Suelo; ArgentinaFil: Blackwell, M.S.A. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Upadhayay, H.R. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Hawkins, J.M.B. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido.Fil: Evans, J. Rothamsted Research. Computational and Analytical Sciences; Reino UnidoFil: Collins, A.L. Rothamsted Research. Sustainable Agriculture Sciences; Reino Unido

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab\u27s use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021